AzTrials
AzTrials

Myocardial InjuryOXAMINCT07772570

Multimodal Biomarkers in Coronary Artery Disease Pathogenesis: The Oxford Acute Myocardial Infarction Study (OXAMI Study)

An observational study of Myocardial Injury and Atherosclerosis Cardiovascular Disease, run by University of Oxford at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such as chest pain (angina). Read more about this study

Who is it for?
Ages 18 to 90 yearsHealthy volunteers can take part
What is being tested?
blood sampling, Intracoronary Imaging and Cardiovascular Magnetic Resonance Imaging
How many people
2,000 participants
Where
1 siteUnited Kingdom
Study dates
May 2012to Dec 2046
How long will I take part?
20 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients presenting with evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND/OR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.

Who may be able to join

  • Evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND/OR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.

Who cannot join

  • Patients in whom safety or clinical concerns preclude participation.
  • Anaemia (Hb <9).
  • Pregnant or breast feeding females.
  • Additional exclusion criteria for patients undergoing MRI
  • claustrophobia which limits / prevents participants from remaining in MRI scanner.
  • patients who cannot lie flat on the scan table.
Show all 11Show fewer
  • patients with metallic implants, pacemakers, implantable defibrillators etc, unless known to be MRI compatible.
  • patients with known allergy to medium of contrast (gadolinium)
  • Additional exclusion criteria for patients undergoing coronary CT angiography
  • patients with a known allergy to iodinated contrast media
  • eGFR< 30 ml/min (stage 3-5 renal disease)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United Kingdom1 site, 1 recruiting
  • Oxford Heart Centre, John Radcliffe Hospital

    Oxford

    Recruiting

Other trials in United Kingdom

About this study

Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such as chest pain (angina). Sometimes a plaque can suddenly break open, causing a blood clot to form and block the artery. This can lead to a heart attack and permanent damage to the heart muscle.

Although much has been learned about coronary artery disease, important questions remain about why some plaques suddenly become unstable, how this affects blood flow through the smallest blood vessels of the heart, and why some patients develop more heart muscle damage than others.

Read more

The Oxford Acute Myocardial Infarction (OxAMI) research programme aims to improve our understanding of these processes. The investigators will study both the disease within the coronary arteries (the "upstream" problem) and its effects on the heart muscle (the "downstream" damage). By examining these together, the investigators hope to understand more clearly how changes in coronary plaques lead to heart injury and how this differs between patients.

Participants undergoing procedures to investigate or treat coronary artery disease provide an important opportunity to study these processes. During coronary angioplasty (also called percutaneous coronary intervention or PCI), a narrow or blocked artery is opened, usually using a small balloon and a stent. This procedure can disturb the underlying plaque in a similar way to the plaque disruption that occurs during a heart attack. Where appropriate, the investigators may therefore collect blood and material released from the plaque during these procedures. Blood may be collected from different locations in the circulation, allowing the investigators to study substances released by the plaque and heart muscle. Material that would otherwise be discarded during treatment may also be collected for laboratory analysis.

The investigators will use several established and newer techniques to examine the coronary arteries, the small blood vessels within the heart, and the heart muscle. These may include detailed imaging from inside the coronary arteries using intravascular ultrasound (IVUS) or optical coherence tomography (OCT). The investigators may also measure blood pressure and flow within the coronary arteries to assess how well the small blood vessels supplying the heart are working.

Non-invasive heart scans may include cardiovascular magnetic resonance (CMR/MRI), cardiac computed tomography (CT) and echocardiography (ultrasound). These techniques can provide detailed information about the structure and function of the heart, blood supply to the heart muscle, areas of injury or permanent scarring, and changes that occur following a heart attack. In particular, MRI may help distinguish heart muscle that has been permanently damaged from muscle that is injured but could potentially recover after blood flow is restored. This may be especially important for participants who arrive at hospital several hours after their heart attack began.

Other measurements may include electrocardiograms (ECGs), which record the electrical activity of the heart, and measurements of heart pressure, volume and function. Some participants may also have longer-term ECG monitoring.

Blood and tissue samples may be analysed using a range of laboratory techniques. These studies will investigate inflammation, blood clotting and other biological processes involved in coronary artery disease and heart attacks. Newer laboratory methods may allow us to measure large numbers of proteins and small molecules in the blood. Material collected from plaques may also be examined under a microscope to identify its cells and structural components.

With additional consent, blood samples may be stored for genetic research. This could help us understand whether differences in people's genes influence their risk of coronary artery disease, their response to a heart attack, or the amount of heart damage that occurs.

By combining information about coronary plaques, blood flow through the heart's circulation, heart muscle injury, imaging, blood and tissue markers, and genetic factors, the OxAMI study aims to build a detailed picture of coronary artery disease and heart attacks. The programme will establish a carefully characterised group of research participants who may contribute to future OxAMI studies conducted under separate research protocols.

Ultimately, this research aims to identify better ways to predict, diagnose and understand coronary artery disease and heart attacks, and to identify new approaches that could improve treatment and outcomes for future patients.

Being tested
blood sampling, Intracoronary Imaging, Cardiovascular Magnetic Resonance Imaging, Cardiac Computerised Tomography, Invasive Coronary Physiology
Medical subject headings
Thrombosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • blood samplingDiagnostic test

    Blood sampling across different periprocedural and follow-up timepoints.

  • Intracoronary ImagingDiagnostic test

    Intracoronary Imaging with approved devices

  • Cardiovascular Magnetic Resonance ImagingDiagnostic test

    Cardiovascular Magnetic Resonance Imaging (Multiparametric Phenotyping)

  • Cardiac Computerised TomographyDiagnostic test

    Photon-counting CT

  • Invasive Coronary PhysiologyDiagnostic test

    Angiography derived, Bolus Thermodilution, Continuous Thermodilution, Doppler Flow

Study groups in NCT07772570
Study groupRoleWhat they receive
Acute Coronary SyndromePatients presenting with Acute Coronary syndrome (ST-segment elevation or non-ST-Segment Elevation
Receives: Diagnostic Test: blood sampling; Diagnostic Test: Intracoronary Imaging; Diagnostic Test: Cardiovascular Magnetic Resonance Imaging; Diagnostic Test: Cardiac Computerised Tomography; Diagnostic Test: Invasive Coronary Physiology
Stable ischemic heart diseasePatients presenting with suspicion of stable ischemic heart disease
Receives: Diagnostic Test: blood sampling; Diagnostic Test: Intracoronary Imaging; Diagnostic Test: Cardiovascular Magnetic Resonance Imaging; Diagnostic Test: Cardiac Computerised Tomography; Diagnostic Test: Invasive Coronary Physiology
Myocardial InjuryPatients presenting with objective evidence of myocardial injury
Receives: Diagnostic Test: blood sampling; Diagnostic Test: Intracoronary Imaging; Diagnostic Test: Cardiovascular Magnetic Resonance Imaging; Diagnostic Test: Cardiac Computerised Tomography; Diagnostic Test: Invasive Coronary Physiology
Healthy ControlsHealthy controls
Receives: Diagnostic Test: blood sampling; Diagnostic Test: Cardiovascular Magnetic Resonance Imaging

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Major adverse cardiovascular events

    Composite of cardiac mortality, heart failure, recurrent myocardial infarction, target vessel/lesion revascularization, life threatening arrhythmia

    Measured: 20 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Aug 2026
  2. Study startMay 2012
  3. Primary completionSep 2046 (estimated)
  4. Study completionDec 2046 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
2,000 participants (estimated)
Target duration
20 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07772570
Sponsor's protocol ID
10120
Acronym
OXAMI
Status last verified
Aug 2026
First submitted
14 Aug 2026
Last updated
24 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data may be shared upon reasonable request

Questions about this trial

What is this clinical trial studying?

An observational study of Myocardial Injury and Atherosclerosis Cardiovascular Disease, run by University of Oxford at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Keith M Channon, MD (+44 1865 287581, keith.channon@cardiov.ox.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Major adverse cardiovascular events (time frame: 20 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in